Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galmed Pharmaceutica (NQ: GLMD )

0.3775 -0.0012 (-0.32%)
Streaming Delayed Price Updated: 1:07 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Galmed Pharmaceutica

< Previous 1 2 3 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers traders need to know about this morning! 
Via InvestorPlace
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model
Via Benzinga
Recap: Galmed Pharmaceuticals Q4 Earnings
Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q4 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Is Clearfield (CLFD) Stock Down 28% Today?
Clearfield (CLFD) stock is falling on Friday after the company released its earnings report for the fiscal second quarter of 2023. 
Via InvestorPlace
Why is Trupanion (TRUP) Stock Down 32% Today?
Trupanion (TRUP) stock is taking a beating on Friday after the pet medical insurance company released its earnings report for Q1 2023. 
Via InvestorPlace
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Galmed Pharmaceuticals (GLMD) stock is gaining on Friday after the company announced an investment agreement with OnKai. 
Via InvestorPlace
Why Carvana Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're diving into the biggest pre-market stock movers traders will want to keep an eye on for Friday morning! 
Via InvestorPlace
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
Why Tuesday Morning Shares Are Trading Lower By 38%; Here Are 31 Stocks Moving Premarket
Gainers Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 106.9% to $0.5482 in pre-market trading on heavy volume. 
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares rose 77.7% to $0.0906 in pre-market trading. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 38 stocks hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 49 companies reached new 52-week lows. 
Via Benzinga
Galmed Pharmaceuticals: Q2 Earnings Insights
  Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
Via Benzinga
Galmed Pharmaceuticals: Q1 Earnings Insights
Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00. Shares of Galmed Pharmaceuticals are trading down... 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Upgrades 
Via Benzinga
Galmed Pharmaceuticals's Earnings Outlook
Galmed Pharmaceuticals (NASDAQ:GLMD) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Galmed... 
Via Benzinga
Galmed Pharmaceuticals Q4 2021 Earnings Conference Call On May 2, 2022 At 08:30 AM ET
Galmed Pharmaceuticals (NASDAQ:GLMD) will host a conference call at 08:30 AM ET on May 2, 2022, to discuss Q4 2021 earnings results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
25 Stocks Moving in Friday's Pre-Market Session
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading... 
Via Benzinga
Earnings Scheduled For May 2, 2022
Companies Reporting Before The Bell • New Gold (AMEX:NGD) is estimated to report quarterly earnings at $0.03 per share on revenue of $212.42 million. 
Via Benzinga
Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of... 
Via Benzinga
Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.